Response rates to second‐line treatment with daratumumab bortezomib dexamethasone ( DVD ) in relapsed/refractory light chain amyloidosis ( AL ) after initial Bortezomib‐based regime
British Journal of Haematology · 2024
DOI: 10.1111/bjh.19529 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Joshua Bomsztyk und 14 weiteren Autor:innen. Beteiligte Einrichtung: National Amyloidosis Centre, University College London, Royal Free Campus, London, UK. Hauptthemen laut MEDLINE: Bortezomib, Dexamethasone, Immunoglobulin Light-chain Amyloidosis, Antibodies, Monoclonal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Bortezomib is regularly used as frontline therapy for systemic AL amyloidosis. We assess the efficacy of second‐line daratumumab‐bortezomib‐dexamethasone (DVD) in AL amyloidosis in bortezomib‐exposed patients. A total of 116 patients treated with second‐line DVD were identified from a prospective observational study of newly diagnosed AL amyloidosis (ALchemy). DVD was initiated in both the relapsed setting or where there was an inadequate response defined as very good partial response (VGPR) or VGPR with organ progression/lack of organ improvement. A complete response (CR)/VGPR to second‐line DVD was achieved in 81 (69.8%) patients. A CR/VGPR was achieved in 67 (79.7%) in those who achieved a VGPR/CR to first line versus 14/32 (43.8%) in those who did not. Where DVD was initiated due to an inadequate response to first line (vs. at relapse), the median event‐free survival (EFS) was 18 vs. 34 months ( p = 0.002). If a CR/VGPR was achieved to DVD, the 2‐year EFS was still lower in those with prior inadequate response 54% vs. 66% ( p = 0.062). DVD is an efficacious second‐line treatment in systemic AL amyloidosis in a bortezomib‐exposed population. However, the response to DVD is poorer in those with an inadequate response to first‐line bortezomib.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Amyloidosis Centre, University College London, Royal Free Campus, London, UK.
- University College London Hospital, London, UK.
ORCID-Profile: Joshua Bomsztyk, Sriram Ravichandran, Jahanzaib Khwaja
Zitieren
APA
Bomsztyk, J., Ravichandran, S., Khwaja, J., Cohen, O., Rauf, M. U., Foard, D., Martinez-Naharro, A., Venneri, L., Whelan, C., Fontana, M., Hawkins, P. N., Gillmore, J., Lachmann, H., Mahmood, S., & Wechalekar, A. D. (2024). Response rates to second‐line treatment with daratumumab bortezomib dexamethasone ( DVD ) in relapsed/refractory light chain amyloidosis ( AL ) after initial Bortezomib‐based regime. British Journal of Haematology. https://doi.org/10.1111/bjh.19529
Vancouver
Bomsztyk J, Ravichandran S, Khwaja J, Cohen O, Rauf MU, Foard D, et al. Response rates to second‐line treatment with daratumumab bortezomib dexamethasone ( DVD ) in relapsed/refractory light chain amyloidosis ( AL ) after initial Bortezomib‐based regime. British Journal of Haematology. 2024. doi:10.1111/bjh.19529
BibTeX
@article{Bomsztyk2024,
author = {Bomsztyk, Joshua and Ravichandran, Sriram and Khwaja, Jahanzaib and Cohen, Oliver and Rauf, Muhammad U and Foard, Darren and Martinez-Naharro, Ana and Venneri, Lucia and Whelan, Carol and Fontana, Marianna and Hawkins, Philip N and Gillmore, Julian and Lachmann, Helen and Mahmood, Shameem and Wechalekar, Ashutosh D},
title = {Response rates to second‐line treatment with daratumumab bortezomib dexamethasone ( DVD ) in relapsed/refractory light chain amyloidosis ( AL ) after initial Bortezomib‐based regime},
journal = {British Journal of Haematology},
year = {2024},
doi = {10.1111/bjh.19529}
}
EUVIMED